Your session is about to expire
← Back to Search
Neuromodulation
Active treatment for Heart Failure
N/A
Waitlist Available
Led By Stavros Stavrakis, MD, PhD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Summary
This trial is testing whether electrical stimulation of the vagus nerve can help treat heart failure with preserved ejection fraction, a condition where the heart doesn't pump blood as well as it should. The study will test whether the treatment can improve symptoms and inflammation.
Eligible Conditions
- Heart Failure
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mitral Valve Insufficiency
Global Longitudinal Strain
Secondary study objectives
Exercise Capacity
Inflammatory Cytokines
Minnesota Living With Heart Failure Questionnaire
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active treatmentExperimental Treatment1 Intervention
Patients will receive 1 hour of active transcutaneous low level vagal stimulation daily for 3 months
Group II: Sham controlPlacebo Group1 Intervention
Patients will receive 1 hour of sham transcutaneous low level vagal stimulation daily for 3 months
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
low level transcutaneous vagus nerve stimulation
2017
N/A
~60
Find a Location
Who is running the clinical trial?
University of OklahomaLead Sponsor
468 Previous Clinical Trials
92,461 Total Patients Enrolled
4 Trials studying Heart Failure
315 Patients Enrolled for Heart Failure
Stavros Stavrakis, MD, PhDPrincipal InvestigatorUniversity of Oklahoma
4 Previous Clinical Trials
777 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger